Abstract：
Pulmonary aspergillosis is a serious pulmonary fungal infectious disease. It is difficult to manage and has limited treatment options. Existing anti-aspergillus medications have high rates of treatment failure and increased drug resistance, making it difficult to meet the clinical requirements. Therefore, the development of new, effective treatment programs is critical. According to research, interferons play an important role in the body\'s immune response to bacterial and viral infectious diseases. Inadequate interferon expression or dysfunction can put the body at risk for certain infectious diseases. Interferon has been used in clinical trials to prevent or treat infectious diseases. In recent years, researchers have focused on the immunological role of interferon in Aspergillus infections and its potential for clinical application. This review summarized the most recent advances in the immunoregulatory mechanisms of interferon and its clinical application in Aspergillus infections.
肺曲霉病是一种严重的肺部真菌感染性疾病，临床诊治困难，现有抗曲霉药物存在治疗失败率高、药物耐药率增加等问题，无法满足临床需求。因此开发新的治疗方案是非常必要的。研究表明，干扰素广泛参与细菌和病毒等感染性疾病的免疫反应。干扰素表达不足或功能缺陷常常导致机体易发生感染性疾病。已有临床研究探索了干扰素在感染性疾病中作为预防或辅助治疗的潜在疗效。近年来，研究者们逐渐开始关注干扰素在曲霉感染中的免疫作用及其在临床应用中的潜力。本综述将总结曲霉感染中干扰素免疫作用及其临床应用的最新研究进展。.
肺曲霉病是一种严重的肺部真菌感染性疾病，临床诊治困难，现有抗曲霉药物存在治疗失败率高、药物耐药率增加等问题，无法满足临床需求。因此开发新的治疗方案是非常必要的。研究表明，干扰素广泛参与细菌和病毒等感染性疾病的免疫反应。干扰素表达不足或功能缺陷常常导致机体易发生感染性疾病。已有临床研究探索了干扰素在感染性疾病中作为预防或辅助治疗的潜在疗效。近年来，研究者们逐渐开始关注干扰素在曲霉感染中的免疫作用及其在临床应用中的潜力。本综述将总结曲霉感染中干扰素免疫作用及其临床应用的最新研究进展。.
摘要：
暂无翻译
